A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00319670|
Recruitment Status : Completed
First Posted : April 27, 2006
Last Update Posted : February 7, 2013
|Condition or disease||Intervention/treatment||Phase|
|Constipation||Drug: MiraLax||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children|
|Study Start Date :||March 2006|
|Actual Primary Completion Date :||May 2006|
- Efficacy will be measured by analysis of patient self-reported BM data.
- Adverse events will be monitored and analyzed for safety purposes.
- Patient acceptance will be measured by analysis of subjective questionnaire data.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00319670
|United States, Massachusetts|
|Boston, Massachusetts, United States, 02115|
|United States, Ohio|
|Youngstown, Ohio, United States, 44514|
|Principal Investigator:||Samuel Nurko, MD||Boston Children’s Hospital|